Collecting Samples From Patients With Autoimmune and Inflammatory Skin Diseases
Collects blood samples from people with immune-related skin diseases to study them.
Plain-language title generated from the registry record
Registry title: Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
Key facts
- Where
- Toulouse, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 99 years old?
Source: NCT06387654, who can take part
Where in France
- University HospitalToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT06387654
- Record updated
- 17 March 2026
- Original description
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.Read full original descriptionShow less
Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.
Inclusion: Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin; The patients included may be adults or children, and will be:; Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others),; Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example),; Patients with cutaneous lupus; Patients with dysimmune skin diseases (psoriasis, eczema); Patients with immuno-induced dermatological disorders or drug dermatitis; Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.); Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected.
Exclusion: Patients under 6 years old; Patients under protective supervision (guardianship, curators); Pregnant or breastfeeding woman.